Minakem Generic APIs Minakem Generic APIs

X

Find the latest Drugs in Development and Pipeline Prospector News of Muscular Dystrophy Association.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Muscular Dystrophy Association
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
161 N. Clark, Suite 3550 Chicago, Illinois 60601
Telephone
Telephone
800-572-1717
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

EDG-5506 is an orally administered investigational therapy small molecule, targets fast skeletal myosin to protect dystrophic muscle and reduce muscle damage biomarkers in a Phase 1 trial in becker muscular dystrophy and duchenne muscular dystrophy.


Lead Product(s): Sevasemten

Therapeutic Area: Genetic Disease Product Name: EDG-5506

Highest Development Status: Phase IProduct Type: Small molecule

Recipient: Edgewise Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 08, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY